Lipella pharmaceuticals secures extended market exclusivity with issuance of u.s. patent for liposomal delivery platform

Pittsburgh, nov. 12, 2024 (globe newswire) -- lipella pharmaceuticals inc. (nasdaq: lipo), a clinical-stage biotechnology company focused on developing innovative therapies for serious diseases with unmet medical needs, today announced that u.s. patent no. 12,138,345 for its proprietary liposomal drug delivery platform will be officially issued by the u.s. patent and trademark office (uspto) on november 12, 2024.
LIPO Ratings Summary
LIPO Quant Ranking